Last reviewed · How we verify
Abiraterone acetate MTD
Androgen receptor inhibitor
Androgen receptor inhibitor Used for Prostate cancer.
At a glance
| Generic name | Abiraterone acetate MTD |
|---|---|
| Also known as | CB7630 |
| Sponsor | Cougar Biotechnology, Inc. |
| Drug class | CYP17 inhibitor |
| Target | CYP17 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Abiraterone acetate is a potent inhibitor of the enzyme CYP17, which is involved in the biosynthesis of androgens. By inhibiting CYP17, abiraterone acetate reduces the production of androgens, such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Nausea
- Muscle spasm
Key clinical trials
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） (PHASE1, PHASE2)
- AMG 386 and Abiraterone for Advanced Prostate Cancer (PHASE2)
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer (PHASE1, PHASE2)
- Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer (PHASE1, PHASE2)
- Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer (PHASE1, PHASE2)
- A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy (PHASE1, PHASE2)
- An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abiraterone acetate MTD CI brief — competitive landscape report
- Abiraterone acetate MTD updates RSS · CI watch RSS
- Cougar Biotechnology, Inc. portfolio CI